Data showing effects of a PI3K-δ inhibitor on neutrophil superoxide production during FPR2 activation and reactivation.
FPR2
Neutrophils
PAFR
PI3K
Reactive oxygen species
Receptor cross-talk
Journal
Data in brief
ISSN: 2352-3409
Titre abrégé: Data Brief
Pays: Netherlands
ID NLM: 101654995
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
28
05
2020
revised:
11
08
2020
accepted:
12
08
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
10
9
2020
Statut:
epublish
Résumé
Reactive oxygen species (ROS) generated by the NADPH oxidase are crucial for antimicrobial host defense and also play a role in the regulation of inflammatory processes. Signals generated by formyl peptide receptor 2 (FPR2) activate the neutrophil ROS generating NADPH oxidase; such signals are mediated when the receptors bind an activating agonist, as well as when agonist desensitized FPR2 are reactivated by the receptor for platelet-activating factor (PAF). We present data on the effects of Idelalisib, a specific inhibitor for the PI3Kδ isoform, on ROS production during FPR2 activation and reactivation by PAF, respectively. Neutrophils were isolated from peripheral blood of healthy adults obtained from the blood bank at Sahlgrenska University Hospital and ROS release was measured using isoluminol-amplified chemiluminescence.
Identifiants
pubmed: 32904194
doi: 10.1016/j.dib.2020.106185
pii: S2352-3409(20)31079-9
pii: 106185
pmc: PMC7452661
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106185Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships which have, or could be perceived to have, influenced the work reported in this article.
Références
Methods Mol Biol. 2020;2087:301-324
pubmed: 31729000
PLoS One. 2014 Oct 10;9(10):e109516
pubmed: 25303226
PLoS One. 2013;8(3):e60169
pubmed: 23555913
Scand J Immunol. 1991 Dec;34(6):697-712
pubmed: 1749920
Biochim Biophys Acta. 2013 Aug;1833(8):1914-23
pubmed: 23562731
J Med Chem. 2017 Aug 24;60(16):6991-6997
pubmed: 28700225